Interaction of ribosomal protein L22 with casein kinase 2α: A novel mechanism for understanding the biology of non-small cell lung cancer

被引:14
作者
Yang, Mingxia [1 ]
Sun, Haibo [2 ]
He, Ji [4 ]
Wang, Hong [3 ]
Yu, Xiaowei [1 ]
Ma, Lei [2 ]
Zhu, Changliang [2 ]
机构
[1] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Resp Med, Changzhou 213000, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Dept Pathogen Biol, Nanjing 210029, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Affiliated Hosp 1, Dept Resp Med, Nanjing 210029, Jiangsu, Peoples R China
[4] Xiamen Entry Exit Inspect & Quarantine Bur, State Key Lab Monitoring & Detect Med Vectors, Xiamen 361012, Fujian, Peoples R China
基金
中国国家自然科学基金;
关键词
non-small cell lung cancer; ribosomal protein L22; TAP; protein-protein interaction; casein kinase 2 alpha; phosphorylation; DOWN-REGULATION; CK2; ACTIVATION; TUMORS; GENE; RNA; RIBOSOMAL-PROTEIN-L22; IDENTIFICATION; SPECIFICITY; EXPRESSION;
D O I
10.3892/or.2014.3187
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dysfunction of ribosomal proteins (RPs) may play an important role in molecular tumorigenesis, such as lung cancer, acting in extraribosomal functions. Many protein-protein interaction studies and genetic screens have confirmed the extraribosomal capacity of RPs. As reported, ribosomal protein L22 (RPL22) dysfunction could increase cancer risk. In the present study, we examined RPL22-protein complexes in lung cancer cells. Tandem affinity purification (TAP) was used to screen the RPL22-protein complexes, and GST pull-down experiments and confocal microscopy were used to assess the protein-protein interaction. The experiment of kinase assay was used to study the function of the RPL22-protein complexes. The results showed that several differentially expressed proteins were isolated and identified by LC-MS/MS, which revealed that one of the protein complexes included casein kinase 2 alpha (CK2 alpha). RPL22 and CK2 alpha interact in vitro. RPL22 also inhibited CK2 alpha substrate phosphorylation in vitro. This is the first report of the RPL22-CK2 alpha relationship in lung cancer. Dysregulated CK2 may impact cell proliferation and apoptosis, key features of cancer cell biology. Our results indicate that RPL22 may be a candidate anticancer agent due to its CK2 alpha-binding and -inhibitory functions in human lung cancer.
引用
收藏
页码:139 / 144
页数:6
相关论文
共 50 条
  • [21] Prognostic significance of protein kinase B/Akt pathway in patients with non-small cell lung cancer
    Mayadagli, Alpaslan
    Gul, Sule Karabulut
    Bilici, Ahmet
    Oruc, Ahmet Fatih
    Kocak, Mihriban
    Ozkan, Alper
    Aksu, Atinc
    Barisik, Nagehan Ozdemir
    Gumus, Mahmut
    JOURNAL OF BUON, 2014, 19 (01): : 157 - 163
  • [22] Detection of novel paraja ring finger 2-fer tyrosine kinase mRNA chimeras is associated with poor postoperative prognosis in non-small cell lung cancer
    Kawakami, Masanori
    Ishikawa, Rie
    Amano, Yosuke
    Sunohara, Mitsuhiro
    Watanabe, Kousuke
    Ohishi, Nobuya
    Yatomi, Yutaka
    Nakajima, Jun
    Fukayama, Masashi
    Nagase, Takahide
    Takai, Daiya
    CANCER SCIENCE, 2013, 104 (11) : 1447 - 1454
  • [23] Novel TKIs in Non-Small Cell Lung Cancer
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1449 - S1449
  • [24] Novel Therapies for Non-Small Cell Lung Cancer
    Donington, Jessica S.
    Koo, Chi Wan
    Ballas, Marc S.
    JOURNAL OF THORACIC IMAGING, 2011, 26 (02) : 175 - 185
  • [25] Pathways regulating the expression of the immunomodulatory protein glycodelin in non-small cell lung cancer
    Weber, Rebecca
    Meister, Michael
    Muley, Thomas
    Thomas, Michael
    Sueltmann, Holger
    Warth, Arne
    Winter, Hauke
    Herth, Felix J. F.
    Schneider, Marc A.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2019, 54 (02) : 515 - 526
  • [26] Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer
    Chen, Bojiang
    Tan, Zhi
    Gao, Jun
    Wu, Wei
    Liu, Lida
    Jin, Wei
    Cao, Yidan
    Zhao, Shuang
    Zhang, Wen
    Qiu, Zhixin
    Liu, Dan
    Mo, Xianming
    Li, Weimin
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2015, 34
  • [27] ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers
    Roskoski, Robert, Jr.
    PHARMACOLOGICAL RESEARCH, 2017, 121 : 202 - 212
  • [28] A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer
    Ramisetty, Sravani
    Kulkarni, Prakash
    Bhattacharya, Supriyo
    Nam, Arin
    Singhal, Sharad S.
    Guo, Linlin
    Mirzapoiazova, Tamara
    Mambetsariev, Bolot
    Mittan, Sandeep
    Malhotra, Jyoti
    Pisick, Evan
    Subbiah, Shanmuga
    Rajurkar, Swapnil
    Massarelli, Erminia
    Salgia, Ravi
    Mohanty, Atish
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (02)
  • [29] KRAS-Mutant non-small cell lung cancer: From biology to therapy
    Ferrer, Irene
    Zugazagoitia, Jon
    Herbertz, Stephan
    John, William
    Paz-Ares, Luis
    Schmid-Bindert, Gerald
    LUNG CANCER, 2018, 124 : 53 - 64
  • [30] Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
    Halvorsen, Ann Rita
    Haugen, Mads Haugland
    Ojlert, Asa Kristina
    Lund-Iversen, Marius
    Jorgensen, Lars
    Solberg, Steinar
    Maelandsmo, Gunhild M.
    Brustugun, Odd Terje
    Helland, Aslaug
    FRONTIERS IN ONCOLOGY, 2020, 10